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Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has killed more than
37,000 people in Italy and has caused widespread socioeconomic disruption. Urgent
measures are needed to contain and control the virus, particularly diagnostic kits
for detection and surveillance, therapeutics to reduce mortality among the severely
affected, and vaccines to protect the remaining population. Here we discuss the
potential role of plant molecular farming in the rapid and scalable supply of protein
antigens as reagents and vaccine candidates, antibodies for virus detection and passive
immunotherapy, other therapeutic proteins, and virus-like particles as novel vaccine
platforms. We calculate the amount of infrastructure and production capacity needed
to deal with predictable subsequent waves of COVID-19 in Italy by pooling expertise in
plant molecular farming, epidemiology and the Italian health system. We calculate the
investment required in molecular farming infrastructure that would enable us to capitalize
on this technology, and provide a roadmap for the development of diagnostic reagents
and biopharmaceuticals using molecular farming in plants to complement production
methods based on the cultivation of microbes and mammalian cells.
Keywords: therapeutics, vaccines, antibodies, diagnostics, recombinant proteins, transient expression,
molecular farming, COVID-19
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INTRODUCTION
Severe acute respiratory syndrome-related coronavirus 2
(SARS-CoV-2) is a new virus responsible for the COVID-
19 pandemic, which is the worst public health crisis of this
century1. The emergence of SARS-CoV-2 in late 2019 and its
rapid spread in 2020 has posed several global challenges that
demand new solutions in public healthcare and the biomedical
research ecosystem (Webb et al., 2020). The former is facing
acute pressure on hospital beds and frontline medical staff,
whereas the latter is experiencing an explosion in new research,
leading to a mountain of rapidly-disseminated literature often
in the form of fast-tracked preprint articles. COVID-19 also
dramatically highlighted the need for preparedness and long-
term investments in platforms suitable for the rapid, flexible and
sustainable production of medical countermeasures (diagnostics,
vaccines, and therapeutics) against emerging, re-emerging, and
bioterrorism-related infectious diseases (Franconi et al., 2018;
Capell et al., 2020).
Italy was the first country in Europe to face a large-scale
COVID-19 outbreak and it is one of the hardest-hit countries in
the EU (Remuzzi and Remuzzi, 2020). Considering the situation
with the resurgence of the disease after summer 2020, our
national system must be prepared to react promptly by finding
and exploiting new and flexible solutions. This requires an
extraordinary effort aiming to capitalize on existing national
expertise at different levels and will also provide assurance in the
face of future pandemics. A major effort should also be done to
build and potentiate the network with other countries in order
to guide decisions in a global perspective always considering
national peculiarities.
In this article, we discuss how plant molecular farming
could provide practical solutions to address the outbreak of
COVID-19 in Italy. Once effective vaccines and therapeutics
are identified, it will be necessary to ramp up manufacturing
to produce the massive numbers of doses needed to protect
the entire population. The current global uneven distribution of
manufacturing capacity is one of the current drawbacks of plant-
based molecular farming as a realistic alternative to conventional
expression systems (Capell et al., 2020; Tusé et al., 2020).
Given this perspective, we have defined the product categories
that would benefit most from molecular farming (diagnostics,
vaccines, and therapeutics) and have calculated the quantities for
each product category that would be needed to meet national
demand, based on official Italian epidemiological reports in the
February–June 2020 period.
Plant molecular farming encompasses a variety of
different expression technologies, ranging from stable nuclear
transformation (transgenic plants) or plastid transformation
(transplastomic plants) to transient expression without stable
transgene integration (Fischer and Buyel, 2020). In the latter
case, this is achieved by the infiltration of adult wild-type
plants—usually tobacco (Nicotiana tabacum) or its relative
Nicotiana benthamiana—with strains of Agrobacterium
tumefaciens or recombinant plant viral vectors carrying the
1https://coronavirus.jhu.edu/
appropriate transgene cassette (McDonald and Holtz, 2020).
Given the urgent need for diagnostics, vaccines, and therapeutics
for a rapidly-spreading novel or re-emerging disease, only
transient expression systems provide the necessary speed and
scalability, and we therefore focus on such systems in this article
(Tusé et al., 2020).
DIAGNOSTIC REAGENTS
The effective management of COVID-19 requires an increase in
diagnostic capacity, particularly the development, manufacture,
and stockpiling of assays to detect the SARS-CoV-2 genome
and/or antigens itself or the antibodies it elicits. The former
assays are used to confirm infections (thus ensuring effective
quarantine measures and priority medical treatment) whereas
antigenic tests or Rapid Tests, in point-of-care (PoC) format,
have emerged as a valid approach in large screening of schools
and vulnerable communities. On the other hand, antibody tests
are used to assess prior infection and immunity status as the
basis for epidemiological surveillance and vaccine studies. The
number of different tests has increased rapidly and many are
being marketed for point-of-care use. However, their accuracy
has not been formally evaluated, and risks of bias, heterogeneity
and limited generalizability have been reported for point-of-care
testing (Bastos et al., 2020). In spite of this, frequent rapid tests are
considered, in the moment of revising this paper, a “game change”
tool before vaccines become available (Rubin, 2020).
Accurate antibody tests for COVID-19 require high-quality
reagents, although differences between analytical and clinical
sensitivity has not yet been defined for any test. The huge demand
for diagnostic kits has highlighted not only the critical shortage
of reagents (recombinant antigens and antibodies) but also the
means to produce them.
Plants have already been shown to produce SARS-CoV
antigens (Demurtas et al., 2016). The nucleoprotein (N),
transiently expressed in N. benthamiana, was recognized by
sera from Chinese SARS-convalescent patients around the time
of the 2003 outbreak. Furthermore, the full-length membrane
(M) protein was produced in plants but not in bacteria due
to unanticipated toxicity (Carattoli et al., 2005). This provided
proof of principle that plants could be used as a robust,
rapid and flexible production system for SARS diagnostic
reagents, potentially allowing the development of immunological
assays for stockpiling in case of recurring SARS outbreaks
(De Martinis et al., 2016).
Many other antigens have been produced in plants for
diagnostic use or the preclinical/clinical evaluation of vaccine
candidates, mostly by transient expression in N. benthamiana.
The yields vary widely, as shown for a selection of antigens
in Table 1. Antigens were selected among those that have
been produced transiently in N. benthamiana plants and for
which final purification yields were reported. In all these cases,
the products were purified by affinity chromatography due to
the presence of N-terminal or C-terminal affinity tags. Such
tags are suitable for diagnostic reagents as long as they do
not interfere with immunoreactivity, which is indeed the case
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Bet V 1 23.4 Santoni et al., 2019
Dul51 4.9 Margolin et al., 2019
CAP256 SU 6.2 Margolin et al., 2019
NS1-ELP-ER 220 Marques et al., 2020
rHAO 200 Kanagarajan et al., 2012
SARS N protein 10 Demurtas et al., 2016
Antibodies
mAb 2G12 (anti-HIV) 100 Sainsbury et al., 2010
mAb 6D8 (anti-Ebola) 500 Huang et al., 2010
mAb 2A10G6 (anti-Zika) 1,500 Diamos et al., 2020
mAb 4E10 (anti-HIV) 250 Zischewski et al., 2016
mAb M12 (tumor-specific) 2,000 Zischewski et al., 2016
Other therapeutics
Griffithsin 1,000 O’Keefe et al., 2009
Griffithsin 519 Fuqua et al., 2015
Subunit vaccine
HAC1 90 Shoji et al., 2011
HAI-05 50 Shoji et al., 2011
VLP-vaccine
HBcAgD176 1,000 Peyret et al., 2015
HPV8 L1DC22 240 Matić et al., 2011
BPV1 LI 180 Love et al., 2012
HA Influenza Virus H5N1 50 D’Aoust et al., 2008
BTV 70 Thuenemann et al., 2013
HBcAg 2,380 Huang et al., 2006
CVPs-Flu epitope 1,100 Lico et al., 2009
CVPs-HIV epitope 600 Marusic et al., 2001
for all the reported examples. The wide range of yields (1–
220 µg/g fresh leaf mass, average 77.4 µg/g) shows that the
feasibility of molecular farming for antigen manufacturing is
exquisitely sensitive to the intrinsic nature of the product
candidate (and also the quantification method). It is not yet
possible to accurately predict yields based on a given candidate
protein sequence, and empirical evaluation is therefore necessary,
including the testing of multiple expression strategies – which is
also facilitated by the scalability of transient expression systems
(Gengenbach et al., 2020).
Most immunological diagnostic tests proposed for the
detection of SARS-CoV-2 antibodies are based on the full-
length viral spike (S) glycoprotein, the shorter external S1
segment, its receptor binding domain (RBD), or the N protein
(Freeman et al., 2020; Klumpp-Thomas et al., 2020; Rosendal
et al., 2020). For example, Amanat et al. (2020) reported a
serological test based on the RBD in a classic direct ELISA
design, in which the plate is coated with the recombinant RBD
produced in mammalian or insect cells. Nevertheless, the surface-
located S protein is under continuous selective pressure by the
immune system, and new reagents would be needed whenever
a new coronavirus subtype arises in the human population
(Ou et al., 2020). In contrast, the N protein is highly conserved
among coronaviruses and is abundantly expressed during the
early stages of infection, triggering a strong antibody response.
This makes it a suitable diagnostic reagent, in combination with
other antigens such as RBD or the more conserved M protein,
to develop pan-reactive coronavirus tests. The S and N proteins
are typically produced in mammalian cells (HEK293) or insect
cells infected with baculovirus vectors. The N protein has also
been expressed in Escherichia coli (Carattoli et al., 2005; Pei
et al., 2005), but differences between the bacterial and eukaryotic
cytoplasmic compartments and the inability of bacteria to carry
out eukaryotic-type post-translational modifications can reduce
the affinity of such recombinant antigens for antibodies present
in serum (Vankadari and Wilce, 2020).
The amount of coronavirus antigen required to detect IgG
and IgM in patient serum ranged from 50–200 ng/well in a
standard 96-well plate assay (Amanat et al., 2020; Freeman
et al., 2020; Klumpp-Thomas et al., 2020; Rosendal et al.,
2020). Based on this, we calculated the quantity of diagnostic
reagent required to meet the demand in Italy, assuming a
mid-range value for sensitive detection (100 ng/well), with two
technical replicates for each individual and accounting for the
fact that immunological tests would be required in quantities
at least equivalent to the molecular assays currently used for
COVID-19 diagnosis. This is because reliable serological tests
are fundamental requirements for long-term follow-up studies in
order to confirm the stability of (neutralizing) antibody responses
and to define the threshold of neutralizing antibodies that
prevents re-infection (Seow et al., 2020). In our calculation for
the number of serological tests required in Italy, we considered
the number of molecular tests performed in Italy between March
and June 2020 as reported by the Italian Health Ministry2. Based
on these criteria, and assuming average yields from Table 1
(77.4 µg/g), two technical repetitions for each patient, an average
biomass of 10 g of infiltrated leaves per N. benthamiana plant
during transient expression, and an average density of plants in a
greenhouse of 75 plants per sq. m., we predict that approximately
up to 6.5 kg of plant biomass would be required per month,
corresponding to 8.7 sq. m. of greenhouse space, to produce
enough reagents for all serological assays in Italy (Table 2).
THERAPEUTICS
Neutralizing Antibodies
Several trials suggest that passive immunotherapy based on the
use of neutralizing antibodies from COVID-19 patients may be
an important weapon in the fight against SARS-CoV-2 (Tortorici
et al., 2020). Several pharmaceutical companies have already
announced phase I trials of monoclonal neutralizing antibodies
that protected animal models against SARS-CoV-2 (Ren et al.,
2020). One of these studies is evaluating REGN-COV2, a cocktail
of two antibodies that bind non-overlapping regions of the
2http://opendatadpc.maps.arcgis.com/apps/opsdashboard/index.html#
/b0c68bce2cce478eaac82fe38d4138b1
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TABLE 2 | Estimates of the surface area of greenhouse necessary to produce the monthly amount of diagnostic or therapeutic reagents or vaccine molecules potentially
required to fight SARS-CoV-2 in the March-June pandemic in Italy.
Therapeutics Vaccine
Diagnostic Reagenta Antibodyb Otherc Soluble Antigend VLPe
Number Kg Number of Kg Kg Number Kg Kg
of tests LFW m2 persons treated LFW m2 LFW m2 of doses LFW m2 LFW m2
Mar 483,623 1.25 1.67 10,376 153334 204445 40983 54644 3,6 × 107 20696 27592 9388 12518
Apr 847,933 2.19 2.92 9,967 147297 196396 39370 52493
May 2,523,838 6.52 8.69 2,756 40723 54298 10885 14513
Jun 1,435,880 3.71 4.95 729 107775 14367 2880 3840
aAmount per test: 100 ng × 2, b9 g per dose, c3 g per dose, d40 µg per dose, e120 µg per dose.
RBD (Baum et al., 2020; Hansen et al., 2020). Recently, Eli/Lilly
disclosed the preliminary findings of randomized, double-
blind, placebo-controlled Phase 2 study BLAZE-1 evaluating
the combination of LY-CoV555 and LY-CoV016, two SARS-
CoV-2 neutralizing antibodies, for the treatment of symptomatic
COVID-19 in the outpatient setting3. The combination cohort
enrolled recently diagnosed patients with mild-to-moderate
COVID-19, who were assigned to 2,800 mg of each antibody or
placebo. The combination therapy significantly reduced viral load
at days 3, 7, and 11. Combination therapy has been generally
well tolerated with no drug-related serious adverse events. These
studies provide a first indication of an effective therapeutic dose
of monoclonal antibodies against SARS-CoV-2 in the range of
5.6 g per patient.
Plants could provide an alternative system for the production
of recombinant anti-COVID-19 antibodies given the efficient
production of antibodies reported in plants, particularly by
transient expression using viral vectors (Donini and Marusic,
2019). Recent examples of plant-derived neutralizing antibodies
and their yields are listed in Table 1. The average yield of about
870 µg/g suggests that molecular farming could provide a useful
complement for traditional manufacturing systems, especially
when antibodies are required rapidly and on a large scale.
In a worst-case scenario, based on the Italian situation in the
middle of March 2020, the proportion of COVID-19 patients
admitted to an intensive care unit (ICU) was 9–11% (Remuzzi
and Remuzzi, 2020). We calculated the amount of antibody
required to meet the demand in Italy by assuming that all ICU
patients would benefit from passive immunotherapy and that
presumably the dose would be similar to that of the plant-derived
cocktail ZMapp for the treatment of Ebola during the 2014
outbreak in West Africa – 9 g per patient (Mulangu et al., 2019).
Based on these criteria, and again assuming average yields from
Table 1 (870 µg/g), a final 70% recovery of highly purified mAb
necessary for intra-venous administration route and the same
values stated above for biomass and plant density in a greenhouse,
we predict that approximately up to 153,000 kg of biomass
would be required per month, corresponding to approximately
204,000 sq. m. of greenhouse space (Table 2).
3https://clinicaltrials.gov/ct2/show/NCT04427501
Other Proteins
In addition to passive and active immunization, antiviral proteins
could provide an additional weapon against the virus during the
infection phase, and other biologics could help to address the
symptoms of COVID-19 such as the cytokine storm provoked by
the initial wave of infection.
Among virus inhibitors, lectins are particularly interesting
from the perspective of plant molecular farming because they are
naturally produced in many higher plants and bind reversibly
to carbohydrates. Given the frequent presence of glycans on
the surface of viruses, lectins have been explored as antivirals
and have been shown to block the infection cycle of HIV,
cytomegalovirus, respiratory syncytial virus, influenza A, and
also several coronaviruses. Indeed, more than 20 different plant
lectins have already been shown to block infections by SARS-
CoV, probably via selective binding to glycans on the S protein
(Keyaerts et al., 2007). One of the best candidates is the algal
lectin griffithsin (Table 1), which shows potent activity against
SARS-CoV but limited toxicity toward human cells, and has been
expressed at high levels in tobacco with average yields of 760 µg/g
(O’Keefe et al., 2009; Fuqua et al., 2015; Hoelscher et al., 2018).
There is preliminary evidence that natural or artificial peptides
can also inhibit viruses (Struck et al., 2011; Mookherjee et al.,
2020) and short heterologous peptides have been successfully
expressed in plants either independently or displayed on the
surface of plant virus nanoparticles or virus-like particles (VLPs)
by genetic fusion to the viral coat protein gene (Lico et al., 2012b).
Furthermore, several approved drugs have been repurposed for
COVID-19 including existing biologics used for anticoagulation
therapy (Barrett et al., 2020) and immunomodulators used
to block inflammatory cytokine signaling pathways (Rizk
et al., 2020). Molecular farming could significantly reduce the
manufacturing time and costs for such products, given that
functional thrombin inhibitors and fibrinolytics (Abdoli Nasab
et al., 2016; Pitek et al., 2018) as well as antibody-based
immunomodulators (Jantan et al., 2015) have already been
expressed successfully in plants.
Using the same strategy described above for passive
immunotherapy, we considered the amount of griffithsin
required in Italy for the treatment of 10% of COVID-19 patients
admitted to ICUs, basing the dosing schedule on preclinical
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studies involving two intranasal doses of 5 mg/kg body mass
daily for 4 days (O’Keefe et al., 2010). We came to a dose of
3 g, assuming an average patient mass of 74 kg (Pierlorenzi,
2010). Based on these criteria, and again assuming average
yields from Table 1 (759.5 µg/g) and the same values stated
above for biomass and plant density in a greenhouse, we predict
that 41,000 kg of plant biomass would be required per month,
corresponding to 55,000 sq. m. of greenhouse space (Table 2).
VACCINES
The race to produce a COVID-19 vaccine began as soon as
the SARS-CoV-2 genome sequence was published, involving
hundreds of academic and industry research groups around
the world using the most innovative biotechnology-based
approaches. Thus far, 232 COVID-19 vaccine clinical trials have
been registered and in some cases phase I safety data are
already available4.
Conventional inactivated or live-attenuated vaccines against
COVID-19 are likely to be efficacious but also difficult to
manufacture and distribute widely, as well as presenting a
risk of reverting to virulence. Subunit vaccines based on
recombinant antigens, such as the S-protein/RBD (or VLPs
displaying said antigens), are more attractive in terms of safety
and manufacturing, and can also be produced by molecular
farming in plants. Table 1 provides some examples of subunit and
VLP vaccines produced in plants, and indicates average yields of
70 and 702.5 µg/g, respectively.
To determine the amount of vaccine antigen needed for a
primary prevention approach in Italy (Table 2), we assumed that
the dose of a soluble subunit vaccine would be the same as that
recommended for the approved quadrivalent influenza vaccine,
i.e., one shot of 40 µg of each antigen per individual, and that the
dose of a VLP vaccine would be the same as that recommended
for the VLP-based hepatitis B vaccine, i.e., one shot of 120 µg
per individual (Mulangu et al., 2019). Such calculation is
consistent with recent Phase 1 trials with the recombinant SARS-
CoV-2 Spike protein adjuvated vaccine NVX-CoV2373, which
showed promising immunogenic response and tolerability with
an antigen dose of 50 µg, split in two administrations of 25 µg
each 21 days apart (Keech et al., 2020). Also the ongoing Phase
2 clinical trial NCT04466085 with another vaccine based on
recombinant RBD domain of the Spike protein, is testing doses
ranging from 50 to 150 µg of antigen per individual. We also
assumed that 60% of the Italian population (36,000,000) would
need to be vaccinated in order to achieve herd immunity. Based
on these criteria, and again assuming average yields from Table 1
(70 µg/g for soluble antigens, 703 µg/g for VLPs) and the same
values stated above for biomass and plant density in a greenhouse,
we calculate that approximately 21,000 kg of plant biomass and
28,000 sq. m. of greenhouse space would be required to satisfy the
demand for a soluble antigen, whereas 9,400 kg of plant biomass
and 12,500 sq. m. of greenhouse space would be required to
produce sufficient quantities of the VLP vaccine (Table 2).
4https://clinicaltrials.gov/ (search term = vaccine and COVID-19)
Antigen-Based Vaccines
Neutralizing antibodies against coronaviruses often block
interactions between the S protein and its receptor. In the case
of SARS-CoV-2, this is angiotensin converting enzyme 2 (ACE2)
primarily found on the surface of lung epithelial cells, although
also in other tissues (Liu et al., 2020; Long et al., 2020). The
S protein or parts thereof are therefore the favored as vaccine
candidates, although the N and M proteins have also been
considered. Previous coronavirus vaccines (against SARS-CoV
and MERS-CoV) induced Th2-mediated immunopathology
in animal models, and researchers are focusing on protein
engineering strategies to minimize this effect (Koirala et al.,
2020). One promising approach is to express the S1 or RBD parts
of the S protein, focusing the immune response on the parts of
the S protein that interact directly with ACE2 and thus increasing
the likelihood of eliciting neutralizing antibodies. The S1/RBD
surface is heavily glycosylated and these proteins are therefore
more effective as antigens when expressed in eukaryotic cells
(Walls et al., 2020). The highest yield of recombinant RBD has
been achieved in yeast, reaching 400 mg/L in the fermentation
supernatant at a production scale of up to 60 L (Chen et al.,
2020). Another promising approach is the fusion of the S-protein
or its components to the Fc region of a human IgG1 antibody,
which prolongs its exposure to the immune system. An S-IgG1
fusion protein produced in CHO-K1 cells elicited promising
immune responses in primates (Ren et al., 2020). According to
the authors, following the theoretical vaccination schedule of the
anti-VZV Shringrix vaccine (two doses of 50 µg) and considering
a yield of 50 mg/L in CHO-K1 cells, 3 million doses of vaccine
could be produced every 14 days in a 3000-L bioreactor. In
the Italian scenario, with a herd immunity threshold of 60%
(36,000,000 people), the required 72,000,000 doses could be
produced in a single 3000-L bioreactor in approximately 1 year.
The S protein of several avian, swine and murine
coronaviruses, as well as the N-terminal fragment of the
SARS-CoV S protein, have been produced successfully in
transgenic maize, potato, tomato, or tobacco plants by classic
Agrobacterium-mediated transformation, or by display on the
surface of plant viruses, and in all cases the products induced an
immune response following oral delivery (Tuboly et al., 2000;
Bae et al., 2003; Lamphear et al., 2004; Zhou et al., 2004) or nasal
delivery (Koo et al., 1999). However, transient expression is more
suitable for the speed and scale of production needed to address
a rapidly-spreading disease live COVID-19. Two companies
are known to be developing a plant-based subunit vaccine
against COVID-19: Kentucky BioProcessing (Owensboro, KY,
United States)5 and iBio (Bryan, TX, United States)6.
VLPs and Chimeric VLPs
VLPs are nanoparticles formed from virus structural proteins –
they resemble the authentic virion but lack the virus genome.
Chimeric VLPs include components of more than one virus,
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the VLP and another provides epitopes to display on the surface.
VLP-based vaccines are already approved for immunization
against hepatitis B virus, papillomaviruses, bluetongue virus, and
Norwalk virus (Balke and Zeltins, 2019; Syomin and Ilyin, 2019)
and more than 100 VLP-based candidate vaccines are currently
undergoing clinical trials7. Several chimeric VLPs displaying
coronavirus peptides identified by in silico analysis or docking
are also in development (Kalitaa et al., 2020; Wang et al., 2020).
VLPs based on plant viruses can be produced on a large scale
by molecular farming (Lico et al., 2011, 2012b; Thuenemann
et al., 2013). The examples listed in Table 1 range from simple
VLPs based on a single viral protein to more complex structures
containing up to four proteins (Marsian and Lomonossoff, 2016).
The strong potential of VLP vaccines made in plants
is demonstrated by the VLPs developed by Medicago Inc.
(QC, Canada) for vaccination against seasonal and pandemic
influenza, which have reached phase III and II clinical trials,
respectively. These vaccines are based on combinations of
hemagglutinin proteins from different viral strains, which
naturally assemble to form VLPs even in the absence of the
other influenza virus structural proteins (D’Aoust et al., 2010).
During the 2009 H1N1 pandemic, the company produced the
first batch of research-grade vaccine only 3 weeks after receiving
the A/H1N1 sequence (D’Aoust et al., 2010).
Although plant-derived SARS-CoV-2 VLPs have yet to be
reported, the feasibility of this approach has been demonstrated
by the successful production of other coronavirus VLPs in insect
and mammalian cells (Lu et al., 2007, 2010; Bai et al., 2008;
Lokugamage et al., 2008). This suggests that SARS-CoV2 VLPs
could be assembled in plants by co-expressing the M, E, and
S proteins. Medicago announced a program to develop a VLP-
based COVID-19 vaccine candidate in July 2020, combining
their recombinant coronavirus virus-like particle (CoVLP)
technology with adjuvants from GlaxoSmithKline and Dynavax
Technologies for the phase I trial8. A VLP-based COVID-19
vaccine program has also been announced by iBio Inc.6 This
company was established with funding from the United States
Defense Advanced Research Projects Agency (DARPA) and was
part of the Blue Angel initiative to establish centers for the rapid
delivery of medical countermeasures in response to emerging
diseases, as demonstrated by the production of ∼10 million doses
of influenza vaccine in only 1 month using its plant-based9.
In addition to SARS-CoV-2 VLPs, another potential route
to a VLP-based COVID-19 vaccine is the production of
chimeric VLPs displaying SARS-CoV-2 epitopes, as previously
shown for human papillomavirus particles displaying influenza
virus antigens (Matić et al., 2011) and hepatitis B virus
particles displaying foot and mouth disease virus antigens
(Huang et al., 2005). In the context of coronaviruses, this








SARS-CoV to the transmembrane domain and C-terminus of
avian influenzavirus hemagglutinin and expressing this with the
avian influenzavirus matrix 1 protein in insect cells (Liu et al.,
2011). Another successful strategy involves the RBD of the
MERS-CoV S protein fused to the canine parvovirus structural
protein VP2, resulting in VLPs that conferred protection and
elicited neutralizing antibodies (Wang et al., 2017). Transient
expression in plants should be able to produce similar VLPs
on a larger scale, and more rapidly than any system based on
cells cultivated in bioreactors. Plant viruses could also be used to
display multiple immunogenic and immunomodulatory peptide
epitopes (Lico et al., 2012a; Santoni et al., 2020), providing
an effective strategy to induce simultaneous immune responses
against different targets and to stimulate different components
of the immune system – innate and adaptive, humoral and
cell-mediated (Lico et al., 2013; Balke and Zeltins, 2019).
DISCUSSION
In many countries, schools have begun and workplaces reopened
in order to restart the economy after the devastating effects of
the COVID-19 lockdown, while several countries are already
experiencing a second epidemic wave (Ali, 2020). In this
context, we have shown how plant molecular farming could
contribute to an effective response strategy in a country
like Italy, where expertise in this field is mainly restricted
to the research sector. National experts were gathered to
envisage the scenario of a second epidemic wave, with a
distribution and infection rate similar to the primary wave,
in order to quantify the potential of plant molecular farming
as a manufacturing platform for the production of diagnostic
reagents, therapeutics and vaccines.
In all our forecasts, we restricted the platform technology
to transient expression, because this allows the rapid initiation
and scale-up of production, generating the first batches in
only a few weeks (Hefferon, 2014). Furthermore, the large-scale
production of recombinant proteins by transient expression is
already considered consistent with good manufacturing practice
in several countries, which is a prerequisite for the manufacture
of pharmaceutical products (Fischer et al., 2012). Plant molecular
farming would require only minimal investment compared to
the expansion of fermenter infrastructure for microbes or animal
cells, and would be much more flexible in the face of emergency
scenarios as seen with COVID-19.
Recent commercial investments in large-scale
automated vertical farming facilities for the production of
biopharmaceuticals have shown that it is possible to process
up to 7.58 kg of biomass per month per sq. m. (Holtz et al.,
2015) and more recently Buyel et al. (2017) reported for a
vertical farming unit yields of 68.25 kg of biomass per month
per sq. m. Therefore, two such facilities would be able to process
enough biomass in one week to meet Italy’s entire demand for
a VLP-based vaccine (sufficient to achieve herd immunity) and
for diagnostic reagents (sufficient to test the entire population)
with only 10% of the capital costs required for fermenter-based
infrastructure. For the production of neutralizing antibodies
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and antivirals such as griffithsin, our projection suggests that
plant molecular farming could provide additional capacity, thus
complementing other biopharmaceutical production platforms
to ramp up the speed and scale of manufacturing at the time
of greatest need. The footprint of such production facilities
could also be reduced by advances that improve the yield of
recombinant protein in plant tissues (Barbante et al., 2008;
Rigano et al., 2009; Avesani et al., 2010) thus lowering unit
costs (Nandi et al., 2016). Our projections for Italy also
suggest that investments in molecular farming infrastructure
could provide a valuable approach for any country looking
to improve its preparedness for a second wave of COVID-
19 and future epidemic or pandemic diseases. Furthermore,
this technology has the main advantage of easy-scalability
that enables to set rapidly the platform on the basis of the
ongoing needs; in a rapidly changing scenario, such as the one
that we are experiencing, this aspect may help in directing
national decisions also on the basis of global experiences,
taking advantage from the global network that has been
recently established.
In this regard, to help consolidate molecular farming in
Europe, the network could benefit from the service offered
by the EU Research Infrastructures (RIs) that are being
established in Europe according to the ESFRI roadmap (program
H2020-EU.1.4.1.2) and will be fully operational in the coming
years. RIs are facilities, resources or services, identified by
European research communities to conduct and to support
top-level research activities in their domains. In particular,
IBISBA (Industrial Biotechnology Innovation and Synthetic
Biology Accelerator10) is an Engineering Biology Research
Infrastructure that brings together research organizations
providing experimental and in silico services for industry and
academia, to accelerate bio-based manufacturing processes.
Furthermore, we believe that joint investments from public
and private funding may help to reach this ambitious goal, having
a major impact on the complex health national eco-system and
possibly contributing in a global perspective to adopt effective
countermeasures in emergency situations as the current one.
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